Rahman 1991.

Methods	Six‐week double blind, multicentre, randomised study.
Participants	Patients meeting DSM‐III for major depressive episode, with a minimum baseline score of 29 on the MADRS. Age range: 61‐86 years old. Exclusion criteria: concurrent depressive delusions or stupor; depression secondary to other psychiatric illness, according to DSM‐III; narrow angle glaucoma; symptoms suggestive of prostatic hypertrophy; history of epilepsy, myocardial infarct within 3 months of entry into the study or any degree of heart block or other clinically significant arrhythmia.
Interventions	Fluvoxamine: 26 participants. Dothiepin: 26 participants. Fluvoxamine dose range: 100‐200 mg/day. Dothiepin dose range: 100‐200 mg/day. Hypnotic and anxiolytic medication was allowed during the study, but other antidepressants were not.
Outcomes	MADRS, CGI‐I, Newcastle Scale. Total dropout, dropout due to side effects, number of patients experiencing at least one side effect.
Funded by pharmaceutical companies	Funded by pharmaceutical company markets fluvoxamine.
Fluvoxamine as an investigational or comparator drug	Unclear.
Notes	Patients with major depressive episode (DSM‐III) were included, so there might be some bipolar depression, but correct number was not reported.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomized", no further details.
Allocation concealment (selection bias)	Unclear risk	No details.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Quote: "double blind", no further details.
Incomplete outcome data (attrition bias) All outcomes	High risk	Study endpoint: 9/26 missing from fluvoxamine group (2 due to adverse effects); 7/26 missing from control group (2 due to adverse effects).
Selective reporting (reporting bias)	High risk	SDs for endpoint score and change score were not reported.